(S (NP (NNP Immunogenicity)) (VP (VBZ is) (NP (DT a) (JJ major) (NN problem)) (PP (IN during) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNS biotherapeutics))))) (SBAR (IN since) (S (NP (PRP it)) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NP (NP (JJ rapid) (NN clearance)) (PP (IN of) (NP (DT the) (NN drug)))) (CC and) (NP (JJ adverse) (NNS reactions))))))))) (. .))
(S (NP (NP (DT The) (NN challenge)) (PP (IN for) (NP (JJ biotherapeutic) (NN design)))) (VP (VBZ is) (ADVP (RB therefore)) (S (VP (TO to) (VP (VB identify) (NP (NP (NNS mutants)) (PP (IN of) (NP (DT the) (NN protein) (NN sequence))) (SBAR (WHNP (IN that)) (S (VP (JJ minimize) (NP (NN immunogenicity)) (PP (IN in) (NP (DT a) (NN target) (NN population))) (SBAR (IN whilst) (S (VP (VBG retaining) (NP (NP (JJ pharmaceutical) (NN activity)) (CC and) (NP (NN protein) (NN function)))))))))))))) (. .))
(S (NP (JJ Current) (NNS approaches)) (VP (VP (VBP are) (ADJP (RB moderately) (JJ successful) (PP (IN in) (S (VP (VBG designing) (NP (NP (NNS sequences)) (PP (IN with) (NP (JJ reduced) (NN immunogenicity))))))))) (, ,) (CC but) (VP (VBP do) (RB not) (VP (VB account) (PP (IN for) (NP (NP (DT the) (VBG varying) (NNS frequencies)) (PP (IN of) (NP (JJ different) (JJ human) (NN leucocyte) (NN antigen) (NNS alleles))) (PP (IN in) (NP (DT a) (JJ specific) (NN population))))))) (CC and) (VP (PP (IN in) (NP (NN addition))) (, ,) (SBAR (IN since) (S (NP (JJ many) (NNS designs)) (VP (VBP are) (ADJP (JJ non-functional))))) (, ,) (VB require) (NP (JJ costly) (JJ experimental) (NN post-screening)))) (. .))
(S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP report) (NP (NP (DT a) (JJ new) (NN method)) (PP (IN for) (NP (NN de-immunization) (NN design))) (VP (VBG using) (NP (NP (JJ multi-objective) (JJ combinatorial) (NN optimization)) (SBAR (WHNP (WDT that)) (S (VP (ADVP (RB simultaneously)) (VBZ optimizes) (NP (NP (DT the) (NN likelihood)) (PP (IN of) (NP (DT a) (JJ functional) (NN protein) (NN sequence)))) (PP (IN at) (NP (NP (DT the) (JJ same) (NN time)) (PP (IN as) (S (VP (VBG minimizing) (NP (NP (PRP$ its) (NN immunogenicity)) (VP (VBN tailored) (PP (TO to) (NP (DT a) (NN target) (NN population))))))))))))))))) (. .))
(S (NP (PRP We)) (VP (VBP bypass) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (JJ three-dimensional) (NN protein) (NN structure)) (CC or) (NP (JJ molecular) (NNS simulations)))) (S (VP (TO to) (VP (VB identify) (NP (JJ functional) (NNS designs)))))) (PP (IN by) (S (VP (ADVP (RB automatically)) (VBG generating) (NP (NNS sequences)) (S (VP (VBG using) (NP (NP (JJ probabilistic) (NNS models)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (VP (VBN been) (VP (VBN used) (ADVP (RB previously)) (PP (IN for) (NP (NP (NN mutation) (NN effect) (NN prediction)) (CC and) (NP (NN structure) (NN prediction)))))))))))))))) (. .))
(S (PP (IN As) (NP (JJ proof-of-principle))) (NP (PRP we)) (VP (VP (VBD designed) (NP (NP (NNS sequences)) (PP (IN of) (NP (NP (DT the) (NNP C2) (NN domain)) (PP (IN of) (NP (NNP Factor) (NNP VIII))))))) (CC and) (VP (VBD tested) (NP (PRP them)) (ADVP (RB experimentally))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (JJ good) (NN correlation)) (PP (IN with) (NP (NP (DT the) (JJ predicted) (NN immunogenicity)) (PP (IN of) (NP (PRP$ our) (NN model)))))))))) (. .))
